On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Five Prime Therapeutics (NASDAQ:FPRX), Arrowhead Research (NASDAQ:ARWR), ISIS Pharmaceuticals, (NASDAQ:ISIS), Celldex Therapeutics, (NASDAQ:CLDX)
Five Prime Therapeutics Inc (NASDAQ:FPRX) declined -4.54%, and closed at $24.79. The company has the market capitalization of $632.96 million. On the other hand the stock’s volatility for the week is 9.93%, and for the month is 6.70%. The stock’s price to book ratio is $6.29, however price to sale ratio is $32.96. Analyst’s mean recommendation regarding this stock is 1.20. (Where 1=Buy, 5=Sale).
Five Prime Therapeutics Inc (FPRX) a clinical-stage biotechnology company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab.
Arrowhead Research Corp (NASDAQ:ARWR) decreased -4.60%, and closed at $7.37. The stock has price to sale ratio of 1346.01, however, price to book ratio is 2.76. With recent decline, the year-to-date (YTD) performance reflected a -2.64% decline below last year. During the past month the stock lose -0.14%, bringing three-month performance to 12.52% and six-month performance to -51%. The mean recommendation of analysts for this stock is 2.30 (where 1=Buy, 5=Sale).
Arrowhead Research Corp (ARWR) develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) decreased -4.53%, and closed at $73.59, hitting new 52-week high of $77.80. The company holds the market capitalization of $8.76 B. For the last twelve months, the stock was able to keep return on equity at -11.60%, while return on assets at –4.60%, in response to its return on investment at -5.70%. Its 20-day moving average gained 5.48%, above 50-day moving average of 7.68%, above 200-day moving average of 52.05% from the latest market price of $73.59. The mean recommendation of analysts for this stock is 2.70. (Where 1=Buy, 5=Sale).
ISIS Pharmaceuticals, Inc. (ISIS) engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) fell -4.41% and closed at $30.38. The stock has the beta value of 2.74, and its volatility for the week is 6.97%, while for the month it is 6.49%. The company has the market capitalization of $2.98 billion. The company holds the book value per share of 2.36, whereas cash per share is 2.05. Price to book ratio remained 12.87, while price to sale ratio is 826.42. Analysts mean recommendation for the stock is said to be 1.30 (where 1=Buy, 5=sale).
Celldex Therapeutics, Inc. (CLDX) a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
